Health Catalyst, Inc. (HCAT) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Full Year 2025 Revenue: $311.1 million, representing 1% year-over-year growth.

Q4 2025 Revenue: $74.7 million, down from $79.6 million in Q4 2024.

Adjusted EBITDA:

Full Year: $41.4 million (59% year-over-year growth).

Q4: $13.8 million, up from $7.9 million in Q4 2024.

Technology Revenue:

Full Year: $208.3 million (7% growth).

Q4: $51.9 million.

Professional Services Revenue:

Full Year: $102.8 million (8% decline).

Q4: $22.8 million.

Adjusted Gross Margin:

Q4: 53.5% (up from 46.6% in Q4 2024).

Full Year: 51.1%.

Dollar-Based Retention Rate: 90%.

Net New Logos: 32 for the year, slightly below the initial target of 40.

2Strategic Updates and Business Highlights

Leadership Transition: Ben Albert has taken over as CEO, focusing on long-term success and operational efficiency.

Strategic Review: A comprehensive assessment of the business is underway to identify areas for improvement and focus.

Operational Changes:

Appointment of general managers for interoperability and cybersecurity.

Transitioning the Chief Commercial Officer role to enhance commercial alignment.

Ongoing search for a COO and CMO to strengthen operational rigor.

Focus on Core Value Proposition: Emphasizing cost management, clinical quality, and consumer growth as key areas of client need.

Simplification of Offerings: Plans to streamline product offerings and improve clarity in communication with clients and investors.

3Forward Guidance and Outlook

Q1 2026 Revenue Guidance: Expected to be between $68 million and $70 million.

Q1 2026 Adjusted EBITDA Guidance: Anticipated between $7 million and $8 million.

Full-Year 2026 Guidance: Not provided; management plans to offer guidance by the next earnings call in May 2026.

4Bad News, Challenges, or Points of Concern

Revenue Decline: Q4 revenue decreased compared to the prior year, primarily due to lower professional services revenue.

Migration Challenges: The transition from DOS to Ignite is causing revenue pressure, particularly in data platform infrastructure.

Client Churn Risks: Approximately $12.5 million in DOS-related ARR churn expected in 2026 and 2027, with an additional $52 million at risk of negotiation.

Impairment Charges: A significant goodwill impairment charge of $110.2 million was recorded due to market cap decreases and revised forecasts, contributing to a net loss of $178 million for the year.

5Notable Q&A Insights

Strategic Review Scope: The strategic review includes evaluating all aspects of the business, with no immediate plans for a sale, focusing instead on enhancing shareholder value.

Client Retention Dynamics: While some clients are downselling, Health Catalyst generally retains enterprise relationships, particularly for applications.

Market Demand: There is a growing need for solutions that manage costs and improve clinical quality, which Health Catalyst aims to address through its offerings.

Operational Efficiency Focus: Management is prioritizing operational efficiency and investments in AI and R&D, despite potential near-term financial pressures. This summary encapsulates the key points from the earnings call, highlighting both the achievements and challenges faced by Health Catalyst, Inc. as they navigate a dynamic healthcare landscape.